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ABSTRACT 24 
Chagas disease has spread to non-endemic areas with human migration. Since no 25 
single reference standard test is available, serological diagnosis of chronic Chagas 26 
disease requires at least two tests. New generation techniques have significantly 27 
improved the accuracy of Chagas disease diagnosis by the use of a large mixture of 28 
recombinant antigens with different detection systems, such as chemiluminescence. The 29 
aim of the present study was to assess the overall accuracy of a new generation kit, 30 
Architect Chagas (cut-off ≥ 1 S/CO, sample relative light units/cut-off value), as a 31 
single technique in the diagnosis of chronic Chagas disease. Architect Chagas showed a 32 
sensitivity of 100% (95% confidence interval, CI = 99.5-100) and a specificity of 97.6% 33 
(95% CI = 95.2-99.9). Five out of six false-positive sera were a consequence of cross-34 
reactivity with Leishmania spp. and all of them achieved results < 5 S/CO. We propose 35 
Architect Chagas as a single technique for screening in blood banks and for routine 36 
diagnosis in clinical laboratories. Only grey zone and positive sera with a result ≤ 6 37 
S/CO would need to be confirmed by a second serological assay, thus avoiding false-38 
positive sera and the problem of cross-reactivity with Leishmania spp. The application 39 
of this proposal would result in important savings in the cost of Chagas disease 40 
diagnosis and therefore in the management and control of the disease. 41 
42 
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INTRODUCTION 43 
Chagas disease or American trypanosomiasis is a parasitic infection traditionally 44 
linked to rural areas of Latin America (1). Based on 2010 data, an estimated 5,742,167 45 
people are infected in 21 Latin American countries (2). The epidemiology of Chagas 46 
disease has changed because of migratory trends and it is now an emerging public 47 
health problem in the United States and Europe (3, 4), notably in Spain, the European 48 
country with the largest number of immigrants from Latin America (3, 5).  49 
The flagellated protozoan Trypanosoma cruzi is mainly transmitted in endemic areas 50 
through contact with the dejections of blood-feeding triatomine bugs (6, 7) and more 51 
rarely by oral transmission through contaminated food (8, 9). The infection may also 52 
occur in both endemic and non-endemic areas through blood transfusion (10), organ 53 
transplant (11), congenital transmission (12) and laboratory accidents (13), allowing the  54 
disease to spread to urbanized areas (14). 55 
Chagas disease occurs in two stages: the acute phase, without symptoms or with 56 
nonspecific manifestations in the majority of cases, and the chronic phase, characterized 57 
by cardiac and/or gastrointestinal disorders. In the chronic indeterminate phase of the 58 
disease most patients remain asymptomatic all their lives (15, 16). 59 
Due to the low and intermittent parasitemia, diagnosis during the chronic phase of 60 
Chagas disease is made by serological methods (10, 15, 16). There are two types of 61 
serological techniques for the detection of anti-T. cruzi antibodies: conventional tests 62 
using a whole parasite antigen, and non-conventional tests based on recombinant 63 
antigens (17, 18). Cross-reactivity, especially in conventional assays, is a particular 64 
problem for the serological diagnosis of Chagas disease in regions where Leishmaniasis 65 
also occurs (15, 19). Although numerous assays are available for diagnosing Chagas 66 
disease, no single test is considered the reference standard (19–21). 67 
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To date, an individual is diagnosed as infected with T. cruzi in the chronic phase 68 
of the disease when the results of two serological tests are positive (17). When 69 
inconclusive or discordant results appear, a third technique (17) or additional samples 70 
are required (22), thereby increasing the cost of diagnosis. The plethora of serological 71 
tests used to identify T. cruzi infections often demonstrate discrepant results, which 72 
makes serum interpretation difficult (22, 23). Moreover, T. cruzi has great genetic 73 
diversity and is currently divided into six genotypes known as discrete typing units 74 
(DTUs TcI-TcVI) (24). Discordant results between assays are often attributed to 75 
antigenic differences among recombinant proteins or T. cruzi DTUs (23, 25). 76 
New generation tests with potentially improved accuracy have been recently 77 
developed. The use of a large mixture of recombinant antigens and the incorporation of 78 
different detection systems, such as chemiluminescence, increase the sensitivity and 79 
specificity of the techniques. Other advantages of new generation tests are automation, 80 
rapidity and high-performance. Among them, Architect Chagas (Abbott Laboratories, 81 
Wiesbaden, Germany), a chemiluminescent microparticle immunoassay (CMIA), uses 82 
four recombinant proteins as the antigen (26–28). 83 
The aim of the present study was to assess the overall accuracy of a new 84 
generation kit that combines a mixture of recombinant proteins with chemiluminescence 85 
(Architect Chagas). The application of this single technique in the diagnosis of chronic 86 
Chagas disease modifies the aforementioned diagnostic recommendations. Accordingly, 87 
it could lead to a reduction in the cost and time of diagnosis and be the first step to reach 88 
a consensus on a standard protocol. 89 
 90 
 91 
 92 
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MATERIAL AND METHODS 93 
Ethics statement. This study was approved by the Clinical Research Ethics Committee 94 
(CEIC) of the Hospital de la Santa Creu i Sant Pau in Barcelona (Project code: IIBSP-95 
CHA-2013-33; CEIC number: 53/2013). All samples were anonymized before being 96 
evaluated and included in the study.  97 
Study population and serum samples. A total of 315 sera of adults attended in the 98 
Hospital de la Santa Creu i Sant Pau of Barcelona (Spain) were used in this work. 99 
Clinical data were recorded by a retrospective review of patient files through the 100 
computer system Systems, Applications and Products for Data Processing (SAP). 101 
Serum samples (conserved at -40ºC) were collected during the period January 2009 to 102 
December 2012 and divided in four panels (I to IV):  103 
Panel I (n = 107): samples of chronic chagasic seropositive patients from endemic 104 
countries for Chagas disease in Latin America diagnosed in Spain (96% from Bolivia, 105 
2% from Argentina, and 2% from Paraguay). 106 
Panel II (n = 125): samples of non-chagasic individuals from both endemic (n = 64) and 107 
non-endemic countries (n = 61) for Chagas disease. 108 
For panels I and II, samples had concordant results for two enzyme-linked 109 
immunosorbent assays (ELISAs) using whole-parasite antigen (ELISAc) (29) and 110 
recombinant antigens (ELISAr) (BioELISA Chagas, Biokit, Lliçà d’Amunt, Spain). 111 
Clinical and epidemiological data were considered for the selection. 112 
Panel III (n = 12): samples of individuals from endemic countries for Chagas disease 113 
with discrepant serological results diagnosed in Spain. These samples had discordant 114 
results for ELISAc and ELISAr and were also tested by a Western blot (WB) (19) in 115 
order to get the final interpretation (11 considered negative and 1 positive). Clinical and 116 
epidemiological data were also considered for the selection. 117 
6 
 
Panel IV (n = 71): samples of patients with other infectious diseases to evaluate cross-118 
reactions (8 individuals with leishmaniasis, 7 with toxoplasmosis, 6 with amebic hepatic 119 
abscess, 3 with malaria, 6 with strongyloidiasis, 1 with visceral larva migrans [VLM], 3 120 
with cytomegalovirus, 7 with human immunodeficiency virus [HIV], 4 with parvovirus 121 
B19, 5 with Epstein-Barr virus [EBV], 5 with hepatitis B virus [HBV], 2 with hepatitis 122 
C virus [HCV], 9 with syphilis, and 5 with Lyme borreliosis). All samples had 123 
serological and/or parasitological or molecular evidence of the infectious diseases 124 
studied.  125 
Serological assays and interpretation of results. Since there is no single widely 126 
accepted reference standard test for the diagnosis of T. cruzi infections, 244 sera were 127 
pre-characterized using two serological tests, according to the WHO recommendations 128 
(17). The remaining 71 samples were taken from patients with other diagnoses (panel 129 
IV). For the sera pre-characterization, the techniques used were two ELISAs, one of 130 
them in house and using sonicated epimastigotes of T. cruzi (ELISAc) (cut-off ≥ 20 131 
units) (29) and the second one with recombinant antigens (ELISAr) (results [sample 132 
ratio absorbance/cut-off value] < 0.9 were considered negative, ≥ 1 positive and the 133 
grey zone was from ≥ 0.9 to < 1). Samples with positive results for both assays were 134 
included in panel I and sera with negative results were included in panel II. Samples 135 
with discordant results by these techniques were included in panel III and they were 136 
tested by an in house WB based on lysate T. cruzi epimastigotes, as described elsewhere 137 
(19). The final interpretation of panel III samples was based on results coinciding in two 138 
out of the three techniques performed; thus, 11 were considered negative, and one 139 
positive. In order to rule out Chagas disease, samples of patients with other infectious 140 
diseases (panel IV) were also analyzed through WB. 141 
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All sera were tested for the presence of T. cruzi antibodies by the CMIA Architect 142 
Chagas assay. This fully automated assay is based on recombinant proteins FP3, FP6, 143 
FP10, and TcF. In aggregate, these four hybrid recombinant proteins represent 14 144 
distinct antigenic regions (30, 31). Testing was performed according to the 145 
manufacturer’s instructions. The chemiluminescent reaction is measured in relative light 146 
units (RLUs). Results are expressed as samples RLUs/cut-off value (S/CO). Ratios < 147 
0.8 are considered negative, ≥ 1 are considered positive, and the grey zone was from ≥ 148 
0.8 to < 1. 149 
Data analysis. The following measures of diagnostic accuracy were calculated (TP: true 150 
positive, TN: true negative, FP: false positive, FN: false negative): sensitivity 151 
(calculated as TP/[TP+FN]), specificity (calculated as TN/[TN+FP]), validity index 152 
defined as the percentage of patients correctly classified (32) (calculated as 153 
[TP+TN]/[TP+TN+FP+FN]), positive and negative predictive values (PPV and NPV), 154 
which are the proportion of correctly diagnosed individuals with positive (PPV) or 155 
negative (NPV) results (33) (calculated as TP/[TP+FP] and TN/[TN+FN], respectively), 156 
positive and negative likelihood ratios (LR+, the highest value being the best result, and 157 
LR-, the lowest value being the best result), which express how many times more or less 158 
frequent the test result is obtained among individuals with the disease compared with 159 
those without the disease (34) (calculated as sensitivity/[1-specificity] and [1-160 
sensitivity]/specificity, respectively), Youden index, which is a measure of the overall 161 
discriminative power of a diagnostic procedure (35) (calculated as 162 
[sensitivity+specificity]-1), and Cohen’s kappa coefficient, which describes the level of 163 
concordance among tests relating the observed agreement (Ao) and the agreement 164 
expected by chance (Ae) (36) (calculated as [Ao-Ae]/[1-Ae]) (values > 0.8 indicate a 165 
high level of agreement) (37). Calculations were performed with the software EPIDAT 166 
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3.1, which is available online at http://www.sergas.es. 167 
Economic evaluation. An economic assessment of the annual cost of Chagas disease 168 
serology in the Hospital de la Santa Creu i Sant Pau in Barcelona was done. During the 169 
period from March 2014 to February 2015, a total of 718 sera were analyzed for the 170 
presence of T. cruzi antibodies in our hospital. Several calculations were done: (i) the 171 
annual cost of performing two assays (Architect Chagas and ELISAr) for all the 718 172 
sera according to the WHO recommendations, (ii) the annual cost of performing 173 
Architect Chagas for all sera and confirming by ELISAr grey zone (2 sera) and all 174 
positive samples (98 sera), and (iii) the annual cost by having to confirm by the second 175 
test only grey zone (2 sera) and positive ≤ 6 S/CO samples (19 sera), strategy proposed 176 
in this study.  177 
 178 
RESULTS 179 
Sera were divided in four panels: panel I (samples of chronic chagasic patients), 180 
panel II (samples of non-chagasic patients), panel III (samples with discrepant 181 
serological results), and panel IV (samples of patients with other infectious diseases).  182 
A coincident result of Architect Chagas with the pre-characterization was 183 
considered as true positive (TP) or true negative (TN) and a discordant result with the 184 
pre-characterization was considered as false positive (FP) or false negative (FN) (Table 185 
1). In this study, no FN for Architect Chagas were observed.  186 
Among the 244 sera pre-characterized as positive or negative for Chagas 187 
disease, 242 were concordant with Architect Chagas results. Only one serum of panel II 188 
tested positive and was considered as FP and one serum of panel III gave a result in the 189 
grey zone. Therefore, the concordance level between pre-characterized sera and the 190 
results obtained with Architect Chagas was 99.2%. 191 
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The overall serum value distribution of ELISAc, ELISAr and Architect Chagas 192 
is shown in Fig. 1. 193 
In reference to TP serum values (n = 108), 94 samples (87.04%) achieved results 194 
> 6 S/CO. The remaining 14 sera (12.96%) obtained values ≤ 6 S/CO; 9 samples 195 
(8.33%) obtained values from 1 to 4.9 and 5 samples (4.63%) from 5 to 6.  196 
When sera from patients with other infectious diseases were analyzed, 5 out of 197 
71 samples were reactive by Architect Chagas. All of them came from Leishmania-198 
infected patients with Chagas disease ruled out by a WB method (19). These FP sera for 199 
Architect Chagas also showed positive results for ELISAc (values between 53 and 84 200 
units) and negative results for ELISAr except in one case in which the sample obtained 201 
a value in the grey zone.  202 
The serum from panel III with a grey zone result for Architect Chagas was 203 
positive for ELISAc (FP), negative for ELISAr, and negative for WB. The serum from 204 
panel IV (Leishmania infection) with a grey zone result for ELISAr was positive for 205 
both ELISAc and Architect Chagas (FP), and negative for WB. These samples were not 206 
included in the calculations, resulting in a final panel of 313 sera.  207 
Measures of diagnostic accuracy of the Architect Chagas assay are shown in 208 
Table 2. Sensitivity, calculated using panels I and III, was 100%. Specificity, calculated 209 
using panels II, III and IV, was 97.6%. FP sera obtained results between 1.8 and 4.6, 210 
and 5 out of 6 samples came from Leishmania-infected patients (Table 3). A high 211 
proportion of patients were correctly classified (validity index of 98.4%) and the test 212 
showed a high level of agreement with the two techniques used in the pre-213 
characterization; Kappa index of 0.91 (95% confidence interval, CI = 0.86-0.95) with 214 
ELISAc and a value of 0.94 (95% CI = 0.90-0.98) with ELISAr. 215 
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ELISAc scored 17 FP, 8 in panel III and 9 in panel IV (7 sera with Leishmania 216 
infection and 2 with EBV). Therefore, the test showed 100% sensitivity (95% CI = 217 
99.5-100), the specificity was 91.7% (95% CI = 87.7-95.7), and the validity index was 218 
94.6% (95% CI = 91.9-97.2). ELISAr achieved 3 FP and 1 FN: 2 FP and the FN in 219 
panel III and 1 FP in panel IV (serum with EBV). Consequently, the sensitivity and 220 
specificity of the technique were 99.1% (95% CI = 96.8-100) and 98.5% (95% CI = 221 
96.7-100), respectively, and the validity index was 98.7% (95% CI = 97.3-100). 222 
The annual cost of performing to assays for Chagas disease diagnosis in our 223 
hospital in Barcelona is €6,864.08 or US$7,413.21. From the 718 samples analyzed 224 
from March 2014 to February 2015, 618 (86.1%) tested negative using Architect 225 
Chagas. Taking into account the 100% sensitivity of the test found in this study, it was 226 
possible to classify the sera as negative with only a single technique. The remaining 100 227 
sera (13.9%) were analyzed by two tests (Architect Chagas and ELISAr), since 228 
Architect Chagas gave grey zone (2 sera, 0.3%) or positive results (98 sera, 13.6%). 229 
Positive samples with results > 6 S/CO (79 sera, 11%) were also analyzed with a second 230 
test (ELISAr), confirming that all of them were TP. This represents an annual cost of 231 
€3,156.08 or US$3,408.57. We propose that grey zone (2 sera, 0.3%) and positive ≤ 6 232 
S/CO (19 sera, 2.6%) samples require further confirmation (TP 57.9%). If inconclusive 233 
results appear, a third technique or additional samples are required. Confirmation by a 234 
second test was only necessary in 21 sera, instead of the 100 positive and inconclusive 235 
samples. As a result, the annual cost by not having to confirm all positive samples 236 
would be €2,682.08 or US$2,896.65 in the hospital population which represents savings 237 
of €4,182 or US$4,516.56 per year. 238 
 239 
 240 
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DISCUSSION 241 
Despite the absence of the vector, Chagas disease is now an emerging public 242 
health problem in Europe and the United States due to immigration from endemic areas 243 
(3, 4). Chronic forms of the disease have appeared in non-endemic countries (4, 38, 39) 244 
as well as acute forms, principally due to vertical transmission (40–42). In Europe, 245 
chronic forms are more abundant than congenital cases. 246 
Chronic forms of Chagas disease are diagnosed serologically, requiring two tests 247 
for confirmation (17). According to the World Health Organization (17), an ideal 248 
serological test should be easy to perform in a single step, be fast, cheap, require no 249 
special equipment or refrigeration of reagents and have 100% sensitivity and specificity, 250 
but unfortunately, no such test exists for Chagas disease. The lack of a reference 251 
standard serological assay for the diagnosis of T. cruzi infection has prompted the 252 
development of new tests, which require further evaluation. Among them, Architect 253 
Chagas, a fully automated assay using four recombinant proteins as the antigen, has 254 
been scarcely studied to date (26–28). 255 
Sera pre-characterization was performed by ELISAc, a conventional method 256 
using parasite lysate as the antigen (29), and ELISAr, based on T. cruzi TcF antigen, a 257 
recombinant fusion protein that comprises four serologically active peptides (PEP-II, 258 
TcD, TcE, and TcLo1.2) (43, 44). The assay evaluated here, Architect Chagas, 259 
incorporates three recombinant proteins (FP3, FP6, and FP10) in addition to the TcF of 260 
ELISAr (30, 31, 45, 46). These four proteins in aggregate represent 14 different 261 
antigenic regions present throughout the life cycle of T. cruzi (30, 45). Moreover, T. 262 
cruzi is currently divided into six DTUs with distinct genetic profiles (24). Architect 263 
Chagas is capable of detecting the genetic diversity of T. cruzi by the incorporation of 264 
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highly conserved antigenic proteins with tandemly repeated amino acid domains (26, 265 
45). 266 
A well-known problem in the serological diagnosis of Chagas disease is cross-267 
reaction with antibodies produced by other pathogens, especially Leishmania spp. (15, 268 
19, 47). All FP sera for Architect Chagas except one (5 out of 6) came from patients 269 
with leishmaniasis (panel IV) (see Table 3). Although all patients were from Spain, 270 
these samples were analyzed by a WB using T. cruzi lysate epimastigotes as antigen 271 
(19) in order to check possible Leishmania spp.-T. cruzi co-infections. Chagas disease 272 
was ruled out in all five cases because of negative results. The remaining FP serum 273 
belonged to a pre-characterized negative patient (panel II) from an endemic area in 274 
which leishmaniasis was ruled out. No data of other possible pathologies of the patient 275 
were known. 276 
In this report, the Architect Chagas recombinant test showed 100% sensitivity, 277 
while specificity was 97.6% due to cross-reactions in the leishmaniasis patients. The 278 
specificity achieved by the Architect Chagas assay excluding cross-reactions with 279 
Leishmania spp. would be 99.5%. Architect Chagas results were highly concordant with 280 
tests using crude antigens, such as ELISAc (Kappa index = 0.91), but with higher 281 
specificity (ELISAc sensitivity 100%; specificity 91.7%). While Architect Chagas gave 282 
positive results in 5 out of 8 sera from Leishmania-infected patients, indicating cross-283 
reactions, ELISAc scored positive results in all the 8 sera with Leishmania spp. The 284 
technique evaluated here also showed a high level of agreement with ELISAr results 285 
(Kappa index = 0.94). Although specificity shown by ELISAr, and even the validity 286 
index, was higher than Architect Chagas, this technique did not detect all positive sera 287 
(ELISAr sensitivity 99.1%; specificity 98.5%; validity index 98.7%). Indeed, Architect 288 
Chagas is better able than ELISAc and ELISAr to discriminate between positive and 289 
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negative sera (see Fig. 1). The higher sensitivity of Architect Chagas is probably due to 290 
the greater diversity of proteins used as antigens, representing the three morphological 291 
forms (trypomastigote, epimastigote and amastigote) and the genetic diversity of T. 292 
cruzi (26, 45). Among current tests in which the number of recombinant proteins is 293 
known, Architect Chagas uses the most. This higher number of recombinant antigens 294 
could also explain the high level of cross-reactions with Leishmania spp. infection. 295 
Consequently, this fact should be considered when studying the diagnosis of Chagas 296 
disease in visceral leishmaniasis endemic areas. Other authors have previously reported 297 
that mixtures of recombinant proteins are very useful as antigens for the 298 
immunodiagnosis of Chagas disease (48, 49).  299 
New generation techniques such as Architect Chagas or Bio-Flash Chagas 300 
(Biokit, Lliçà d’Amunt, Spain) (50) have improved the diagnosis of Chagas disease 301 
with innovative new tools (large mixture of recombinant antigens and 302 
chemiluminescence as detection system). Previous studies have also proposed a 303 
chemiluminescent ELISA (CL-ELISA) with purified trypomastigote glycoproteins for 304 
the detection of lytic protective antibodies against T. cruzi in human sera (33, 51, 52). 305 
CL-ELISA achieved high diagnostic accuracy in both endemic (51, 52) and non-306 
endemic areas (33). Detection systems such as chemiluminescence increase light 307 
amplification and signal duration in comparison with traditional ELISA assays. 308 
Both characteristics, a larger number of recombinant antigens and signal 309 
amplification, lead to higher accuracy in the diagnosis of Chagas disease compared to 310 
conventional and recombinant techniques used in this study.  311 
Other authors have evaluated Architect Chagas using different populations or 312 
sample conditions (26–28). Their overall results (26–28) suggest Architect Chagas is a 313 
highly suitable assay for the detection of chronic T. cruzi infection and its use as a 314 
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single technique for routine testing in high-prevalence areas has already been 315 
recommended (26). In contrast with what is proposed here, a reduction from 1 to 0.88 in 316 
the CO value has been recommended, but only when blood samples on filter paper are 317 
used (28).  318 
According to the results in the present study, and preserving the manufacturer’s 319 
criteria for the interpretation of results, we propose Architect Chagas, or other similar 320 
new generation tests, as a single technique for the diagnosis of chronic Chagas disease 321 
in blood banks and clinical laboratories in both endemic and non-endemic areas. Taking 322 
into account the positive and cross-reactivity results obtained and the overall 323 
distribution of serum values (see Fig. 1C), we suggest that only grey zone and positive 324 
sera with results ≤ 6 S/CO would need to be confirmed by a second serological assay, in 325 
agreement with WHO recommendations. Sera with these results represented less than 326 
18% of positive samples and 6.3% of the total sera analyzed in this study. Further 327 
studies with other new generation techniques with similar characteristics (recombinant 328 
antigens and chemiluminescence) are necessary. 329 
Several control measures exist for Chagas disease, according to the different 330 
transmission scenarios (7, 14, 53), some of which have been applied by health 331 
organizations or administrative governments (54–58). Previous studies on the cost-332 
effectiveness of Chagas disease management have been undertaken (59–62), but the 333 
costs of different diagnostic methods have not been compared.  334 
The adoption of a single high performance technique, like the one studied here, 335 
would entail a significant saving. Indeed, the savings would be €4,182 or US$4,516.56 336 
per year in our hospital, if the comparison is with the cost of performing two assays for 337 
all sera, the WHO-recommended strategy used to date. Our proposal would allow the 338 
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optimization of screening procedures and cost according to the document of the Sixty-339 
third World Health Assembly (63). 340 
According to Sicuri et al. (59), 1.7 million migrants from Latin American 341 
countries endemic for Chagas disease live in Spain, where 42,173 adult immigrants are 342 
estimated to be infected with T. cruzi (64). By 2009, in Europe an estimated 68,000 to 343 
122,000 Latin American immigrants were thought to be infected by T. cruzi, but only 344 
4,290 of them were diagnosed (65). Although Chagas disease has become a real 345 
problem for countries hosting Latin American migrants, not all European countries 346 
screen for the infection (57, 66), a problem that may have been exacerbated by the 347 
recent economic crisis (57). Therefore, the management of Chagas disease in non-348 
endemic countries is crucial to control infection. For an individual with chronic Chagas 349 
disease, the estimated average lifetime cost of health-care is US$27,684, with 350 
considerable variations between countries (60). Other authors have reported that, in the 351 
long term, it is cheaper to diagnose and treat individuals with Chagas disease than not 352 
(61). Accordingly, the high rate of underdiagnosis in non-endemic countries could be 353 
increasing the final cost of Chagas disease patients. The use of a single technique would 354 
reduce diagnosis costs and therefore allow the application of screening and control 355 
programs in countries where such systems have not yet been implemented. 356 
In conclusion, Architect Chagas is a highly effective assay for the detection of 357 
Chagas disease, with 100% sensitivity, and it allows the correct diagnosis of the 358 
majority of samples when applied as a single technique. Architect Chagas can be used 359 
as a single assay in blood banks and clinical laboratories for routine diagnosis. Only 360 
grey zone and positive sera with a result ≤ 6 S/CO would need to be confirmed by a 361 
second serological assay to avoid both FP sera and cross-reactions with Leishmania spp. 362 
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The application of this proposal would result in important savings in the cost of Chagas 363 
disease diagnosis, and therefore in the management and control of the disease. 364 
365 
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TABLES 609 
Table 1. Overview of the results obtained with the Architect Chagas assay for the 610 
four panels of sera studied. 611 
  Pre-characterized sera Other infections Total 
  Panel I 
(n=107) 
Panel II 
(n=125) 
Panel III 
(n=12) 
Panel IV 
(n=71) 
 
(n=315) 
CMIA Positive 107 1 1 5 114 
Negative 0 124 10 66 200 
 Grey zone 0 0 1 0 1 
 Total 107 125 12 71 315 
 612 
 613 
 614 
 615 
 616 
 617 
 618 
 619 
 620 
 621 
 622 
 623 
 624 
 625 
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Table 2. Measures of diagnostic accuracy of the Architect Chagas assay results. 627 
Measure Result 
(numerator/denominator)
95% CI 
Sensitivity (%) 100 (108/108) 99.54-100 
Specificity (%) 97.56 (200/205) 95.21-99.92 
Validity index (%) 98.40 (308/313) 96.85-99.95 
PPV (%) 95.58 (108/113) 91.34-99.81 
NPV (%) 100 (200/200) 99.75-100 
LR+ 41.00 17.25-97.45 
LR- - - 
Youden index 0.98 0.95-1 
95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative 628 
predictive value; LR+, positive likelihood ratio; LR-, negative likelihood ratio. 629 
 630 
 631 
 632 
 633 
 634 
 635 
 636 
 637 
 638 
 639 
 640 
 641 
 642 
 643 
 644 
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Table 3. False positive (FP) serum results of the Architect Chagas assay (n = 6).  645 
FP sera Architect Chagas 
(S/CO)  
Other infections 
1 2.22 Unknown 
2 1.83 Leishmaniasis 
3 4.57 Leishmaniasis 
4 4.09 Leishmaniasis 
5 3.21 Leishmaniasis 
6 2.40 Leishmaniasis 
S/CO, sample relative light units/cut-off value. 646 
 647 
FIGURE LEGEND 648 
Figure 1. Overall serum value distribution of ELISAc (A), ELISAr (B) and 649 
Architect Chagas (C). Sera from panel I (samples from chronic chagasic seropositive 650 
patients, n = 107), panel II (samples from non-chagasic patients, n = 125), panel III 651 
(samples with discrepant serological results, n = 12) and panel IV (samples from 652 
patients with other infections, n = 71) are represented. Full circles () indicate true 653 
positive and negative results, empty circles () indicate false positive and negative 654 
results, and crosses () represent results in the grey zone. Dashed lines represent the 655 
cut-off value established for each test: 20 units for ELISAc (A), 1 absorbance/ cut-off 656 
value for ELISAr (B) and 1 relative light unit/ cut-off value for Architect Chagas (C). 657 
Dotted line in C indicates the point of 6 relative light units/ cut-off value in the Y-axis.  658 

